Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bupleurum granules (Chaihu Keli) is a Traditional Chinese Medicine (TCM) preparation developed and manufactured by Jiangsu Feima Pharmaceutical (also known as Jiangsu Pegasus Pharmaceutical). It is derived from the dried root of *Bupleurum chinense* DC. or *Bupleurum scorzonerifolium* Willd. The preparation is primarily used to treat symptoms associated with the common cold and influenza, such as fever, headache, and cough. In TCM theory, it is used to "resolve the exterior and clear heat" (解表散热), specifically targeting Shao Yang syndrome, which manifests as alternating chills and fever, chest fullness, and irritability. The active constituents include saikosaponins, which exhibit antipyretic, anti-inflammatory, and hepatoprotective properties. It is an approved pharmaceutical product in China, typically administered as an oral granule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupleurum granules.